CoQ10 is a vitamin-like nutrient that plays a vital role in cellular energy
production. It is also known as ubiquinone because its chemical structure is
that of a quinone and it is ubiquitously distributed in nature. The USP refers
to CoQ10 as Ubidecarenone.
Who discovered CoQ10?
CoQ10 was discovered by Dr. Frederick L. Crane at the University of Wisconsin
in the late 1950s during his research on the biochemistry of the mitochondrial
electron transport chain, also known as the respiratory chain.1 The pure
substance isolated from beef heart mitochondria was sent to Dr. Karl Folkers at
the pharmaceutical company Merck for identification and elucidation of its
structure. It was designated coenzyme Q10 because of its quinone structure and
the ten isoprene unit side chain. During the same time period, another group of
scientists led by Dr. R. A. Morton in England isolated the same substance from
mitochondria and named it ubiquinone because of its widespread occurrence in
nature. The vital role of CoQ10 in the electron transport chain was first
described by Dr. Peter Mitchell of England who was awarded the Nobel prize for
his work.
What is the chemical nature of CoQ10?
The chemical structure of CoQ10, elucidated by Dr. Karl Folkers and his
group, is 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone.2 The chemical
identification number (called CAS #) assigned to ubiquinone is 303-98-0, and for
ubiquinol (the reduced form of CoQ10) it is 992-78-9. The structures of
ubiquinone and ubiquinol are shown below.
What are the properties of CoQ10?
The physicochemical characteristics of CoQ10 (Ubiquinone and Ubiquinol) are
shown in Table 1(a) and 1(b).
Table1(a): Properties of Ubiquinone (CoQ10)
CAS Registry No: 303-98-0
Appearance
Orange crystals (at room temperature)
Empirical formula
C59H90O4
Molecular weight
863.358
Melting point
49° C
Solubility
Insoluble in water
Limited solubility in oils and fats
Soluble in nonpolar solvents
Table 1(b): Properties of Ubiquinol (CoQ10 H2)
CAS Registry No: 992-78-9
Appearance
White to very pale yellow crystalline powder
Empirical formula
C59H92O4
Molecular weight
865.37
Melting point
49.5° C
Solubility
Practically insoluble in water.
Limited solubility in oils and fats.
Soluble in nonpolar solvents.
Where does CoQ10 occur in nature?
CoQ compounds are widely distributed in nature, from microorganisms
to plants to animals including humans. In humans and several other species, the
side chain is comprised of 10 isoprene units and hence the name CoQ10.
Animal products such as beef, pork and chicken are relatively good sources of
CoQ10. Organ meats such as heart and muscle are the best sources. As a general
rule, tissues with high energy demands contain relatively high amounts of CoQ10.
Among foods of plant origin, broccoli and spinach contain significant amounts of
CoQ10. Unrefined vegetable oils such as soybean oil and palm oil are also good
sources of CoQ10.
How is CoQ10 synthesized in our body?
CoQ10 is present in almost all the cells in our body and also in
circulation (in lipoproteins). Practically every cell has the ability to
synthesize CoQ10. The endogenous synthesis of CoQ10 happens to be a very complex
process requiring numerous vitamins such as vitamin B6, vitamin B12, folic acid,
niacinamide, pantothenic acid and vitamin C, and also certain trace elements.
The quinone ring structure is derived from the amino acid tyrosine, the methyl
groups on the ring supplied by methionine, and the isoprenoid side chain coming
from the mevalonate pathway (the same pathway shared by cholesterol). Thus the
production of CoQ10 is dependent on an adequate supply of numerous precursors
and cofactors, and a deficiency of one or more of these essential components can
adversely affect the production of adequate amounts of CoQ10.
Figure 2: Synthesis of coenzyme Q10
How is CoQ10 produced commercially?
Commercial production of CoQ10 is largely by way of yeast fermentation, and
to a smaller extent by bacterial fermentation. There is also a semisynthetic
process for producing CoQ10 using solanesol, a tobacco byproduct, that provides
the phytyl side chain, and the amino acid tyrosine for the ring structure. At
this time, most of the world supply of CoQ10 comes from Japan, with smaller
quantities coming from China, India, South Korea and Italy. In the US, natural
CoQ10 is now being produced in a large plant in Pasadena, Texas.
What is the difference between “natural” and “synthetic” CoQ10?
CoQ10 occurs in two isomeric forms, namely the “trans” and the “cis”
forms. The natural CoQ10 is in the trans form whereas the synthetic CoQ10
contains a mixture of both trans and cis isomers. The USP limits the presence of
other CoQ analogs and the cis-isomer and related impurities to less than 1.5%.
How is CoQ10 absorbed in our body?
CoQ10 is a fat-soluble substance and therefore it is absorbed like any other
fat in our diet. Digestion helps in the release of dietary CoQ10 from the food
matrix. For CoQ10 supplements that are based on pure CoQ10, gastric digestion
may not be necessary. In the small intestine, secretions from the pancreas and
bile facilitate emulsification and micelle formation that are required for the
absorption of fats along the small intestine. There is no “active” transport
mechanism for the absorption of fats. Once CoQ10 is taken up by the intestinal
mucosal cells, it is transported via the lymphatic system as part of the
chylomicrons and eventually taken up by the liver for repackaging into
lipoprotein particles and rereleased into the circulation.
How is CoQ10 distributed in the tissues?
CoQ10 is present in all tissues in our body. In blood it is associated with
lipoproteins. The concentrations vary from tissue to tissue, and those with high
rates of metabolic activity and high energy demands such as the heart, muscle,
liver, kidney and brain contain relatively high concentrations of CoQ10.3,4
The redox state of CoQ10 (oxidized vs. reduced, i.e. ubiquinone vs. ubiquinol)
also varies from tissue to tissue, and those with high aerobic activity
generally contain higher amounts of the oxidized form. In circulation, CoQ10 is
present predominantly in the reduced form (as ubiquinol). The ratio of oxidized
to the reduced form in blood may serve as a measure of in vivo oxidative
stress5. Recent studies have shown that the level of circulating Ubiquinol tends
to decline in certain disease conditions, such as diabetes, liver disease, down
syndrome, etc. 48, 49, 50 with the result that the ratio of
circulating Ubiquinol to total Coenzyme Q10 goes down.
How is the status of CoQ10 assessed?
In humans, plasma or serum CoQ10 concentrations will serve as a good
indicator of status. The best way to assay CoQ10 is by HPLC (high pressure
liquid chromatography) by UV or electrochemical detection. However, it should be
noted that plasma CoQ10 may not always reflect tissue status. Localized
deficiencies of CoQ10 may exist such as in the skeletal muscle or myocardial
tissue while plasma concentrations may show “normal” values. If biopsy
material is available, tissue CoQ10 analysis can yield more useful information.7
What are the pharmacokinetic parameters of CoQ10?
Normal serum/plasma CoQ10 concentrations (in healthy individuals) usually
range from 0.5 µg to 1.0 µg per mL. The total body pool of CoQ10 is estimated
to be between 1.5 - 2 gm in a healthy adult. Upon oral administration of CoQ10,
plasma or serum concentrations reach a maximum (Cmax) at about 6 hours (Tmax).
The half-life (i.e. the time to reach half-maximum concentration (T1/2) of CoQ10
is about 34 hours. With the ingestion of high doses of CoQ10, plasma CoQ10
levels have been found to plateau after a dose of 2400 mg a day.8
What does CoQ10 do in our body?
The primary function of CoQ10 in our body is in cellular energy production.
It is a critical component of mitochondria that are present in practically every
cell in our body. Mitochondria may in fact be considered as fuel cells where
biological energy called ATP (adenosine triphosphate) is produced. CoQ10 is also
a potent antioxidant and it helps protect the tissues and the cellular
components in the body from free radical damage. In addition, CoQ10 has other
important functions in the body.4,9
How does CoQ10 work in our body?
CoQ10 is a crucial component of the electron transport chain (respiratory
chain) in the mitochondria where energy derived by a process called oxidative
phosphorylation from the products of fatty acid, protein and carbohydrate
metabolism is converted into biological energy called adenosine triphosphate
(ATP) that drives cellular machinery and all biosynthetic processes. CoQ10
functions as an essential cofactor for the activities of the enzyme systems
called complexes I, II and III in the electron transport chain. It shuttles
electrons from complex I (nicotinamide adenine dinucleotide dehydrogenase) and
Complex II (succinate dehydrogenase) to complex III (ubiquinone-cytochrome c
reductase) by virtue of its redox (reduction-oxidation) properties. It is during
this process of electron transfer along the electron transport chain that vital
biological energy as ATP is generated (Figure 3). Thus, CoQ10 plays a critical
role in cellular bioenergetics.4,9,10,11
CoQ10 is also an important fat-soluble antioxidant and as such, it helps
protect vital structures from free radical damage from both endogenous and
exogenous sources. CoQ10 has other important functions too in the body. It helps
maintain membrane stability and has a role in cell signaling.4,9
Figure 3: Coenzyme Q10 and energy production
What is the role of CoQ10 in supporting our health?
Because of its fundamental role in cellular bioenergetics and also as an
important antioxidant, CoQ10 plays a vital role in our well-being. Since it is
involved in the pathophysiology of numerous disease states listed in the next
section, assuring adequate CoQ10 status is essential for maintaining good health
and preventing or reducing the risk for numerous chronic degenerative and
metabolic diseases.
What are the clinical conditions and health benefits associated with CoQ10?
There is a large body of data on the beneficial effects of CoQ10
supplementation in various disease states.12-19 The following list
shows health problems that are associated with impaired CoQ10 status, and also
numerous disease states and conditions where CoQ10 supplementation has been
found to be beneficial.
Table 2: Potential Beneficial Effects of CoQ10 Supplementation
Cardiovascular disease tops the list of disorders, and there is substantial
evidence for the therapeutic role of CoQ10 supplementation in heart failure.
CoQ10 has also been found beneficial in various other conditions related to the
heart and the cardiovascular system.13-16,20-23 In addition to its
basic function in cellular bioenergetics, CoQ10 has an important role as an
antioxidant in maintaining cardiovascular health by way of protecting LDL from
oxidation.24,25
The role of CoQ10 in neurodegenerative diseases has received a great deal of
attention in recent years.18,26,27 Preliminary evidence for a
beneficial effect of high doses of CoQ10 supplementation particularly in the
case of Parkinson’s and Huntington’s diseases is indeed promising.28,29
Animal data on the role of CoQ10 in amyotrophic lateral sclerosis is also
provocative.30 The importance of CoQ10 in the treatment of
mitochondrial diseases that involve multisystem disorders is also well
recognized.31-34
What are good sources of CoQ10?
Animal-based products and in particular organ meats such as heart are
relatively good sources of CoQ10. But in reality, it is not likely that one
could consume large quantities of any organ meat needed to obtain a reasonable
amount of CoQ10 from dietary sources. CoQ10 supplements are therefore desirable
and bioenhanced formulations of CoQ10 are available that can provide adequate
amounts in a readily absorbable form.
Is CoQ10 a dietary essential?
CoQ10 is not considered a dietary essential because it is synthesized in our
body. However, it could be called a “conditionally essential” nutrient
because the endogenous production may not meet the requirements under certain
conditions. There are several examples of conditionally essential nutrients such
as Taurine, carnitine and choline. Furthermore, the production of CoQ10 is known
to slow down as we age, starting from the 20s.3,4
Is there a “Recommended Dietary Intake” value assigned to CoQ10?
There is no RDI or DV for CoQ10 since it is not considered an essential
dietary nutrient. However, it should be noted that under certain conditions, the
endogenous production of CoQ10 may not be able to keep up with the body’s
demand, and in such situations supplemental CoQ10 is indicated.
Does our diet supply adequate amounts of CoQ10?
The average diet supplies only a small amount of CoQ10. It is estimated that
a typical Western diet provides about 5 mg CoQ10 a day.35 While CoQ10
supplementation may not be necessary for young adults, it is certainly desirable
for physically active adults, and especially for the elderly as a group, since
the production of CoQ10 declines with age.3
What is the relationship between CoQ10 and other nutrients in the body?
There is a great deal of synergy between CoQ10 and various other antioxidants
and nutrients in the body. The antioxidants include both nonenzymatic and
enzymatic defense systems. Among the nonenzymatic antioxidants that interact
with CoQ10 either directly or indirectly are vitamin E, vitamin C, alpha lipoic
acid, and glutathione resulting in augmentation of overall antioxidant potential
due to regeneration and recycling and this would translate into functional
benefit.
What types of CoQ10 supplements are available on the market?
The commonly available supplements are all based on CoQ10 (Ubiquinone) powder
in the form of tablets, two-piece capsules and oil based softgel (soft gelatin)
capsules. A solubilized formulation of CoQ10 called Q-Gel® was introduced in
1996. Q-Gel® has been shown to possess superior bioavailability when compared
with many other products on the market. More recently, a chewable tablet
(ChewQ®) has been introduced which has also shown considerably enhanced
bioavailability. A highly absorbable liposomal formulation called Liquid Q®
(nano-dipersion) was also introduced recently. The marketed formulations of
CoQ10 are all based on ubiquinone, the oxidized form. While CoQ10 also occurs in
its reduced form as ubiquinol, it happens to be highly unstable. Tishcon
Corporation overcame this problem and introduced for the first time a novel
ubiquinol product as a solubilized and stabilized formulation (Q-Nol®,
Li-Q-Nol®) several years ago. Recently Kaneka has introduced QH™ (Ubiquinol)
in powder from which is now available in softgels.
Is there a difference in the bioavailability of CoQ10 supplements?
Yes. Most commonly available formulations of CoQ10 on the market are based on
the powder, in the form of tablets, two-piece capsules, or softgel capsules
containing an oil suspension. Pure CoQ10 is insoluble in water and has limited
solubility in oils and fats. Because of this property, the powder based products
show poor dissolution in aqueous media, and have shown relatively poor
bioavailability in human testing. In order to improve the dissolution profile of
CoQ10, a solubilized formulation of CoQ10 (Q-Gel®) was developed in 1996 that
has shown superior bioavailability as compared with many other product forms.
This enhanced bioavailability claim is based on both laboratory tests
(dissolution test and cell culture studies using Caco-2 cells) and human and
animal studies.36-42 The relative bioavailability of CoQ10 in its
reduced form as ubiquinol has been shown to be higher than that of CoQ10 in its
oxidized form as ubiquinone in both animal and human studies.39,40 In
a recent trial with human subjects, the superior bioavailability profile of
ubiquinol was clearly demonstrated when it was tested alone.43
Li-Q10® is a liquid preparation containing solubilized CoQ10 and it has also
been shown to be superior to the other product forms in laboratory tests and in
human bioavailability studies.39,40 Li-Q10® thus represents an ideal
formulation with enhanced bioavailability for patients requiring oral CoQ10
therapy such as infants, children, elderly, and those with difficulty
swallowing. Anther product that is well-suited for individuals who do not wish
to or are unable to swallow tablets or capsules is ChewQ®, a pleasant tasting
chewable CoQ10 tablet formulation which has shown enhanced bioavailability via
laboratory tests based on dissolution testing and cell culture studies involving
CoQ10 uptake by Caco-2 cells.42 The in vitro dissolution test is
considered a good indicator of in vivo bioavailability. Dissolution test results
of various product types are shown below.
Table: Typical Dissolution Profiles of Various Coenzyme Q10 Products
Product
Dissolution (%)
Compressed Tablets1
0-3
Hardshell Caps
(powder-filled)1
0-3
Softgel Caps
(oil suspension)1
0-3
Chewable wafers1
0-5
ChewQ® wafers2
75-80
Hydro-Q-Sorb®
(powder)
75-100
Q-Gel®
(softgel caps)3
90-100
Q-Nol®
(softgel caps)4
90-100
Liquid Q® (Liquisorb®)
(aqueous nanodispersion)5
100
1Formulated with Coenzyme Q10, USP. 2Formulated with HydroQsorb®. US Patent No. 6,861,447 3Formulated via the Biosolv® process. US Patent No. 6,056,971 4Formulated via the Q-Nol® process. US Patent No. 6,740,338 5US Patent No. 6,455,072 ® Registered Trade Marks of Tishcon Corp.
Are daily divided doses of CoQ10 supplements better than a single dose?
Yes, and this is generally true of any dietary supplement ingested in high
doses.
Is there a recommended way to take CoQ10 supplements?
Yes. As a general rule, dietary supplements should be taken with food. This
assures better absorption and also minimizes or avoids any possible stomach
discomfort.
Are there any contraindications for the use of CoQ10 supplements?
Yes. There are a couple of case reports indicating that high dose CoQ10
supplementation may interfere with anticoagulant (warfarin) therapy but this has
not been verified in a controlled clinical trial. However, it is prudent that
anyone on anticoagulant therapy consult with their health care provider before
using CoQ10 supplements.17
Since there is no data on the safety of CoQ10 supplementation in pregnant or
lactating women, its use is not recommended for these populations.
What are some of the adverse drug interactions with CoQ10?
The most significant ones to date are the adverse effects of
cholesterol-lowering drugs (called statins) on CoQ10 status.44 Since
cholesterol and CoQ10 share the same biosynthetic pathway, inhibition of
cholesterol production in the body also impairs CoQ10 synthesis. Beta-blockers
have shown to decrease endogenous serum CoQ10 levels by inhibiting
CoQ10-dependent enzymes.17 Furthermore, CoQ10 supplementation has
been reported to reduce insulin requirements in diabetes mellitus. Additionally,
some oral hypoglycemic agents including glyburide, acetohexamide, and tolazamide
have also been shown to decrease endogenous CoQ10 levels. Therefore, diabetic
patients taking CoQ10 may require dosage adjustments of hypoglycemic agents.17
Are there any adverse effects due to ingestion of high doses of CoQ10?
Documented side effects associated with the use of high doses of CoQ10
ranging anywhere from 30 mg to as high as 1,200 mg day in humans have been minor
that are related to gastrointestinal problems.14,20 They include
epigastric discomfort, appetite suppression, nausea and diarrhea in a very small
number of cases. One interesting observation is that ingestion of CoQ10 late in
the evening might cause insomnia15 and this may be due to increased
energy levels.
Is the safety of high dose CoQ10 supplementation well-documented?
Yes. The safety of high doses of orally-ingested CoQ10 in the form of
ubiquinone over long periods is very well documented in the literature.14,23
The only side effects reported with a small number of subjects are mild
gastrointestinal symptoms such as nausea and stomach upset.14,17,23
In a recent study, doses as high as 3000 mg a day were found to be safe and
tolerable in patients with Parkinson’s disease.8 According to
Hathcock, et al45 the observed safe level (OSL) of CoQ10 for chronic
administration as a dietary supplement is 1200 mg/day. In a recent trial on the
safety of CoQ10 in its reduced form as ubiquinol in human subjects, dosages of
up to 300 mg daily for two months was found to be safe.43 Higher
dosages were not tested in this study.
Safety data on high dose CoQ10 ingestion are also available based upon animal
studies. In one study with rats, long term ingestion of CoQ10 at doses up to
1200 mg/kg body weight was found to be safe and well tolerated.46 In
another study on the in vivo and in vitro mutagenic potential of CoQ10 based
upon mouse bone marrow micronucleus, chromosomal aberration, and bacterial
reverse mutation tests, CoQ10 did not exhibit any clastogenic activity when
administered orally to mice at doses up to 2000 mg/kg/day. In addition, the
CoQ10 did not induce chromosomal aberrations in CHL/IU cells exposed to high
concentrations, nor did it induce reverse mutations in S. typhimurium and E.
coli.47
Are there any clinical trials on CoQ10 sponsored by the US Government?
There have been numerous studies on CoQ10 supported by the National
Institutes of Health (USA) and carried out under INDs (Investigational New
Drug). These have included Parkinson’s and Huntington’s diseases with
promising results. Another multicenter clinical trial just getting
started at the University of Florida (Principal Investigator: Dr. Peter
Stacpoole) is on the efficacy of oral CoQ10 supplementation in patients with
mitochondrial cytopathies (Tishcon Corporation is providing the Liquid CoQ10
(Ubiquinol) active and placebo formulations for this study).
What is the regulatory status of CoQ10?
CoQ10 is available as a dietary supplement in the US and in several other
countries. It is grandfathered under the Dietary Supplement Health and Education
Act (DSHEA) passed by the US Congress in 1994. Coenzyme Q10 is official in the
United States Pharmacopeia, European Pharmacopeia and the Japanese Pharmacopeia.
Kaneka’s CoQ10 has been self affirmed GRAS – opening the market for its use
in foods.
CoQ10 has also been marketed as a drug for heart disease in Japan for many
years.
Ubi-Q-Gel®, the solubilized formulation of CoQ10 (GelTec/Tishcon Corp.) has
been awarded an Orphan Drug Designation by the US FDA for the treatment of
mitochondrial cytopathies. Ubi-Q-Nol®, the stabilized reduced form of CoQ10
(GelTec/Tishcon Corp.) has also been awarded Orphan Drug Designations for the
treatment of Huntington’s Disease and Pediatric Congestive Heart Failure.
What are the significant milestones in CoQ10 research and in the evolution of
CoQ10 products?
CoQ10 timeline:
1957
CoQ10 first isolated from beef heart mitochondria
- Dr. Frederick L. Crane, University of Wisconsin.
1958
Chemical structure of CoQ10 determined
- Dr. Karl Folkers and colleagues at Merck, Sharpe and Dohme.
1960s
Patients with CHF successfully treated with CoQ7 for the first time
-
Dr. Y. Yamamura in Japan.
1975
“Protonmotive Q cycle” in the mitochondrial electron transport chain
proposed by Dr. P. Mitchell in England.
1978
Dr. P. Mitchell awarded the Nobel prize for elucidating its mechanism of
action.
1980s
Renewed interest in the use of CoQ10 for heart disease. Several
double-blind studies in the US and elsewhere (led by Dr. K. Folkers and his
colleagues) documenting its efficacy.
Exploration of the potential usefulness of CoQ10 for various other
indications including mitochondrial cytopathies.
1987
Publication of the authoritative book on CoQ10 “The Miracle Nutrient
Coenzyme Q10” by Dr. E. G. Bliznakov.
1990s
Increased awareness of the potential health benefits and soaring
popularity of CoQ10 as a dietary supplement.
1994
Passage of Dietary Supplement Health and Education Act (DSHEA) by the US
Congress. CoQ10 grandfathered as a dietary supplement.
1996
Introduction of Q-Gel®, the solubilized CoQ10 with enhanced
bioavailability (GelTec/Tishcon Corp.).
1998-present
Numerous studies documenting the superior performance of Q-Gel® and other solubilized CoQ10 products. Publication of findings in several
peer-reviewed journals and presentations at various scientific meetings.
1999
Orphan Drug Designation awarded by the FDA for CoQ10 (as Q- Gel®,
Tishcon Corp.) for the treatment of mitochondrial cytopathies.
Introduction of
solubilized and stabilized ubiquinol (Q-Nol®, Li-Q-Nol®) by
GelTec/Tishcon Corp.
2001
Publication of USP monographs on CoQ10.
2003
Two additional Orphan Drug designations awarded by the FDA for CoQ10 as
ubiquinol (Q-Nol®, Tishcon Corp.) for the treatment of Huntington’s Disease
and Pediatric Congestive Heart Failure.
2004
Introduction of CoQ10-cyclodextrin complex as HydroQSorb®
(Tishcon Corp.) with superior bioavailability for solid dosage form
applications.
2005
Introduction of Liquid Q® (Tishcon) a nanodispersion of CoQ10
in water – with superior bioavailability.
2006
2006 Introduction of Ubiquinol QH by Kaneka.
To take the test for this course click here to add the course to the shopping cart.
Note: You will need to add the course to the shopping cart and create a nutrilearn.com account, if you don't already have one. The test is
FREE, but you need a nutrilearn.com account to access the test. After you have completed the checkout process, you will be able to access the test through your nutrilearn.com profile.
To access your profile, visit http://www.nutrilearn.com
and click on "sign in". Enter your email address and password you used when you created your nutrilearn account. Once you are signed in to the system, click on "courses" in the top right corner of the page. From there you will be able to see the link to
the COENZYME Q10 Q-FACTS -EXAM.
References
1. Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef
heart mitochondria. Biochim Biophys Acta 1957;25:220-1.
2. Shunk, C.H., Linn, B.O., Wong, E.L., Wittreich, P.E., Robinson, F.M. and
Folkers, K. (1958) Coenzyme Q: Synthesis of 6-farnesyl- and 6-phytyl-
derivatives of 2,3- dimethoxy-5-methyl benzoquinone and related analogs. J. Am.
Chem. Soc. 1958;80:4753.
3. Aberg F, Appelkvist EL, Dallner G, Ernster L. Distribution and redox state
of ubiquinones in rat and human tissues. Arch Biochem Biophys. 1992;295:230-4.
4. Ernster L, Dallner G. Biochemical, physiological and medical aspects of
ubiquinone function. Biochim Biophys Acta, 1995;1271:195-204.
5. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and
ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem.
1997;250:66-73.
6. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and
myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme
Q10. Proc Natl Acad Sci U S A 1985;82:901-4.
7. Steele PE, Tang PH, DeGrauw AJ, Miles MV. Clinical laboratory monitoring
of coenzyme Q10 use in neurologic and muscular diseases. Am J Clin Pathol.
2004;121 Suppl:S113-20.
8. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages
of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol.
2004;188:491-4.
9. Crane F L. Biochemical functions of coenzyme Q10 J Am Coll Nutr
2001;20,591-8.
10. Rauchova H, Drahota Z, Lenaz G. Function of coenzyme Q in the cell: Some
biochemical and physiological properties. Physiol Res 1995;44:209-16.
11. Nohl H, Kozlov AV, Stanick K, Gille L. The multiple functions of coenzyme
Q. Bioorg Chem 2001;29:1-13.
12. Bliznakov EG, Hunt GL. In: The Miracle Nutrient Coenzyme Q10. Bantam
Books, New York, 1987.
13. Littarru GP. In: Energy and Defense. C.E.S.I., Rome, 1995.
14. Sinatra ST. In: The Coenzyme Q10 Phenomenon. Keats Publishing, New
Canaan, CT, 1998.
15. Pepping J. Coenyzme Q10. American Journal of Health-System Pharmacy
1999;56:519-521.
16. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme
Q10 in health and disease. Eur J Clin Nutr 1999;53:764-70.
17. Fuke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential
functions and clinical trials. US Pharmacist 2000;25:1-12.
18. Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative
diseases. Free Rad Res 2002;36:455-460.
19. Bliznakov EG, Chopra RK, Bhagavan HN. Coenzyme Q10 and neoplasia:
Overview of experimental and clinical evidence. In: Phytopharmaceuticals in
Cancer Chemoprevention, Eds. Bagchi D, Preuss HG, CRC Press, Boca Raton,
2004;599-622.
20. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular
disease. J Clin Pharmacol 1990;30:596-608.
21. Langsjoen HA, Langsjoen PH, Langsjoen PH, Willis R, Folkers K. Usefulness
of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med
1994;15 (Suppl):S265-72.
22. Soja AM, Mortensen SA. Treatment of congestive heart failure with
coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol aspects Med
1997;18:S159-68.
23. Langsjoen PH, Langsjoen AM. Overview of the use of coenzyme Q10 in
cardiovascular disease. Biofactors 1999;9:273-84.
24. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10
results in increased levels of ubiquinol-10 within circulating lipoproteins and
increased resistance of human low-density lipoprotein to the initiation of lipid
peroxidation. Biochim Biophys Acta 1992;1126:247-54.
25. Alleva R, Tomasetti M, Bompadre S, Littarru GP. Oxidation of LDL and
their subfractions: kinetic aspects and CoQ10 content. Molecular Aspects of
Medicine, 1997;18 (Suppl):S105-12.
26. Beal MF, Shults CW. Effects of Coenzyme Q10 in Huntington's disease and
early Parkinson's disease. Biofactors. 2003;18:153-6.
27. Beal
MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and
Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg
Biomembr. 2004;36:381-6.
28. Shultz CW, Oakes D, Kieburtz K, Beal FL, Haas R, Plumb S, Juncos JL, Nutt
J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL,
Kurlan R, Molho E, Harrison M, Lew M, and the Parkinson Study Group.
Effects of coenzyme Q10 in early Parkinson Disease. Arch Neurol
2002;59:1541-50.
29. Kieburtz K [The Huntington Study group]. A randomized, placebo-controlled
trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology
2001;57:397-404.
30. Ferrante RJ, Andreassen, OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch
SM, Beal FL. Therapeutic effects of coenzyme Q10 and remacemide in transgenic
mouse models of Huntington’s disease. J Neurosci 2002;22:1592-9.
31. DiMauro S, Hirano M. Mitochondria and heart disease. Curr Opin Cardiol.
1998;13:190-7.
32. Fosslien E. Mitochondrial medicine--molecular pathology of defective
oxidative phosphorylation. Ann Clin Lab Sci. 2001 Jan;31(1):25-67.
34. Lodi R, Rajagopalan B, Bradley JL, Taylor DJ, Crilley JG, Hart PE,
Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Mitochondrial
dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Free Radic Res. 2002 Apr;36(4):461-6.
35. Weber
C, Bysted A, Holmer G. The coenzyme Q10 content of the average Danish
diet. Int J Vitam Nutr Res. 1997;67:123-9.
36. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative Bioavailability
of coenzyme Q10 formulations in human subjects. Int J Vit Nutr Res.
1998;68:109-13.
37. Chopra RK, Goldman R, Bhagavan HN. Relative Bioavailability of coenzyme
Q10 formulations, J Am Pharmaceut Assoc 1998b;38:262.
38. Bhagavan HN, Chopra RK, Sinatra ST. Absorption and bioavailability of
coenzyme Q10. In: Coenzyme Q10 in mitochondrial disease, Ed. Ebadi, M., Publ.
Prominent Press, Scottsdale, 2001;143-9.
39. Miles MV, Horn P, Miles L, Tang P, Steele P, DeGraw, T. Bioequivalence of
coenzyme Q10 from over the counter supplements. Nutr Res 2002:22:919-29.
40. Zaghloul A-a, Gurley B, Khan M, Bhagavan H, Chopra R, Reddy I.
Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug
develop Ind Pharm 2002;28:1195-1200.
41. Molyneux S, Florkowski C, Lever M, George P. The bioavailability of
coenzyme Q10 supplements available in New Zealand differs markedly. N Z Med J.
2004 Oct 8;117(1203):U1108-13.
42. Craft NE, Tucker RT, Chitchumroonchokchai C, Failla M, Bhagavan HN.
Assessment of coenzyme Q10 bioavailability using a coupled in vitro
digestion/Caco-2 human intestinal cell model. FASEB J. 2005;19:A449.
43. Hosoe K, Kitano M, Kishida H, Kubo H., Fujii K, Kitahara M. Study on
safety and bioavailability of ubiquinol (Kaneka QH™) after single and 4-week
multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol.
2007;47:19-28.
44. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of
coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors
(statins): A critical review. Adv Therap. 1998;15:218-28.
45. Hathcock J. ,Shao A. Risk assessment for coenzyme Q10 (Ubiquinone). Regul
Toxicol Pharmacol. 2006;45:282-8.
46. Williams KD, Maneke JD, Abdelhameed M, Hall RL, Palmer TE, Kitano M,
Hidaka T. 52-Week oral gavage chronic toxicity study with ubiquinone in rats
with a 4-week recovery. J Agric Food Chem. 1999;47:3756-63.
Evaluation of the mutagenic potential of ubidecarenone using three short-term
assays. Food Chem Toxicol. 2006;44:364-70.
48. LIM S.C., et al. Oxidative burden in prediabetic and diabetic
individuals: evidence from plasma coenzyme Q10. 2006 Diabetic Medicine, 23,
1344-1349.
49. Hasegawa, et al. Daily profile of plasma % CoQ10 level, a biomarker of
oxidative stress, in patients with diabetes manifesting post prandial
hyperglycemia. 2005 Acta Diabetol, 42: 179-181.
50. Yamamoto Y, et al. Plasma Ubiquinone to Ubiquinol ratio in patients with
hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous
transluminal coronary reperfusion. 1999, BioFactors, 9: 241-246.